Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Applied Materials -- Ignore unavailable to you. Want to Upgrade?

To: StanX Long who wrote (58768)	1/14/2002 3:19:14 AM
From: StanX Long	Read Replies (1) \| Respond to of 70976

"OT" BioReliance Shares Fall On Earnings Outlook washingtonpost.com By Michael Greenspon Washington Post Staff Writer Monday, January 14, 2002; Page E03 BioReliance Corp. has been flying high since the beginning of October. In the week before the first anthrax discovery, BioReliance stock fell 15 percent, to $11.20. The next week it rose 88 percent, to close at $21 a share, a 52-week high at the time. Shares continued to rise on speculation that BioReliance, which already had contracts to provide smallpox vaccine to the Defense Department, would receive more contracts as the federal government built a stockpile of the vaccine. On Dec. 17 the stock hit a 52-week high of $39. On Wednesday, BioReliance chief executive Capers W. McDonald put a damper on the enthusiasm. After his comments, BioReliance fell nearly 33 percent that day on volume that was more than 26 times heavier than its average. BioReliance released an estimated earnings outlook for the first quarter of 2002 that was significantly lower than the quarter that had just ended. The company gave an earnings range of 15 cents to 19 cents per diluted share, compared with 21 cents to 26 cents expected for the quarter that had ended.